Shares of Evolent Health (NYSE:EVH) plummeted by 32.11% in after-hours trading on November 7, 2024, following the release of the company's disappointing third-quarter financial results and lower full-year guidance.
For the third quarter, Evolent Health reported an adjusted loss per share of $0.27, missing analysts' consensus estimate of $0.34 earnings per share by a wide margin. The company's revenue for the quarter came in at $621.4 million, slightly lower than the expected $627.2 million.
Evolent Health also lowered its full-year 2024 adjusted EBITDA guidance to a range of $160 million to $175 million, down from its previous expectations. The company cited challenges in certain areas of its business for the disappointing performance and reduced outlook.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。